Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

WHAT'S NEW

  • Federal Medicaid Cuts
  • Generic Drugs
  • High-Deductible Plans
  • Gun Violence Trauma
  • Hospital Nutrition

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Oct 5 2018

Full Issue

MiMedx's Limit On Range Of Products It Sold To VA Forced Government To Buy More Expensive Treatments

At Veterans Affairs and Department of Defense hospitals, The MiMedx Group -- which manufactures skin grafts and injectable products from donated placental tissues -- didn’t offer the small sizes of two popular products it offered elsewhere. As a result, the government agencies had to buy bigger, more expensive offerings for smaller treatments, former employees said.

The Wall Street Journal: MiMedx Kept Cheaper Products Out Of Its Offerings To VA Hospitals

The MiMedx Group, a maker of amniotic-tissue products, is a major supplier to government-run hospitals and says its products help heal wounded service members and veterans. But an examination of the embattled company’s dealings with Veterans Affairs hospitals and those run by the Defense Department shows that MiMedx’s sales to these entities came at a high cost to taxpayers. According to former employees and company product lists, MiMedx limited the range of products it offered to federal buyers, forcing the government to buy more expensive products than it needed for some very common treatments. (Morgenson, 10/5)

In other veterans' health care news —

Cleveland Plain Dealer: Cleveland VA Medical Center Under Review For Cancellation Of Patients' Tests

The Louis Stokes Cleveland VA Medical Center is among several Veterans Affairs hospitals in the country that are under review for claims they are improperly canceling a large number of patients' diagnostic tests. About 300,000 canceled radiology tests at VA medical centers across the United States since 2016 has raised questions about whether some medically important tests were canceled improperly, according to USA Today. (Washington, 10/4)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, May 5
  • Monday, May 4
  • Friday, May 1
  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF